The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.
BioNTech painted a bleak picture of its operations on Tuesday as the German drugmaker swung to a quarterly loss and announced the departure of its co-founders. BioNTech posted a loss of 1.25 euros a ...
GlobalData on MSN
BioNTech co-founders step down to launch new mRNA venture
The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.
Add Yahoo as a preferred source to see more of our stories on Google. The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, ...
BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...
BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results